

Registro Español de Acontecimientos Adversos de Terapias Biológicas en Pacientes Reumáticos (BIOBADASER)

First published: 06/07/2010

Last updated: 20/08/2024

Network

Network identification

PURI

<https://redirect.ema.europa.eu/resource/4915>

Network ID

4915

Network countries

☐ Spain

Network website

<http://biobadaser.ser.es>

ENCePP partner

No

Network description

BIOBADASER collects actively information on relevant adverse events occurring during the long term treatment with biologic therapies in patients suffering rheumatic diseases. The objective of the register is to identify adverse events in daily practice conditions, to estimate the risk of adverse events, and to assess the survival of the biologics in the long term. BIOBADASER is the result of a collaborative effort of the Spanish rheumatologists (100 centers in phase 1 and 14 in phase 2), the Research Unit of the Spanish Foundation for Rheumatology (FER), the Spanish Agency for Medicines and Medical Devices (AEMyPS) and the Spanish Society of Rheumatology (SER).

Network details

Network primary therapeutic area:

- Musculoskeletal and joint diseases
-

Network funding:

- • Other
- • Pharmaceutical company and other private sector

Contact

Maria Rubi Mazarias

Main

miguelangel.descalzo@ser.es

Martin Maria Auxiliadora

Alternate

mauxiliadora.martin@ser.es